ArticleBMC pharmacology2006
Pharmacological profiles of opioid ligands at kappa opioid receptors.
Article in BMC pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 74 citations in OpenAlex.
- A small dose of dezocine suppresses remifentanil-induced cough in general anesthesia induction: a prospective, randomized, controlled study.BMC anesthesiology · 2020Trial
- Interaction of Analgesic Effects of Dezocine and Sufentanil for Relief of Postoperative Pain: A Pilot Study.Drug design, development and therapy · 2020Trial
- Trial
- Intravenous dezocine pretreatment reduces the incidence and intensity of myoclonus induced by etomidate.Journal of anesthesia · 2014Trial
- Xylazine potentiates the interoceptive effects of fentanyl in male and female rats.Psychopharmacology · 2026Article
- Opioid receptor agonist-antagonists in pain management: receptor specific mechanisms, dose response relationships, and clinical combination strategies.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Kappa opioid receptor control of motivated behavior revisited.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Roles of peripheral and central µAmerican journal of physiology. Lung cellular and molecular physiology · 2025Article
- Genetics-Based Targeting Strategies for Precise Neuromodulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Etorphine induces pathophysiology in immobilized white rhinoceros through sympathomimesis that is attenuated by butorphanol.Conservation physiology · 2025Article
- Dezocine Exerts Analgesic Effects in Chronic Pain by Activation of κ- and μ-Opioid Receptors and Inhibition of Norepinephrine and Serotonin Reuptake.Pain research & management · 2025Article
- The acute adverse health effects of kratom: an evaluation of case reports.Frontiers in pharmacology · 2025Review
- Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.CNS neuroscience & therapeutics · 2024Review
- Machine-learning repurposing of DrugBank compounds for opioid use disorder.Computers in biology and medicine · 2023Article
- Dezocine as a potent analgesic: overview of its pharmacological characterization.Acta pharmacologica Sinica · 2022Review
- Nitrosyl factors play a vital role in the ventilatory depressant effects of fentanyl in unanesthetized rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.BMC cancer · 2021Article
- "I'll Be Back": The Resurrection of Dezocine.ACS medicinal chemistry letters · 2021Article
- Glutathione ethyl ester reverses the deleterious effects of fentanyl on ventilation and arterial blood-gas chemistry while prolonging fentanyl-induced analgesia.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a human embryonic kidney cell system stably expressing only the mouse kappa-opioid receptors. Receptor activation was assessed by measuring the inhibition of cyclic adenosine mono phosphate (cAMP) production stimulated by 5 microM forskolin. Intrinsic activities and potencies of these ligands were determined relative to the endogenous ligand dynorphin and the kappa agonist with the highest intrinsic activity that was identified in this study, fentanyl.
resultsAmong the ligands studied naltrexone, WIN 44,441 and dezocine, were classified as antagonists, while the remaining ligands were agonists. Intrinsic activity of agonists was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The absolute levels of inhibition of cAMP production by each ligand was used to describe the rank order of intrinsic activity of the agonists; fentanyl = lofentanil > or = hydromorphone = morphine = nalorphine > or = etorphine > or = xorphanol > or = metazocine > or = SKF 10047 = cyclazocine > or = butorphanol > nalbuphine. The rank order of affinity of these ligands was; cyclazocine > naltrexone > or = SKF 10047 > or = xorphanol > or = WIN 44,441 > nalorphine > butorphanol > nalbuphine > or = lofentanil > dezocine > or = metazocine > or = morphine > hydromorphone > fentanyl.
conclusionThese results elucidate the relative activities of a set of opioid ligands at kappa-opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of these opioid ligands at this receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.